Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Current Assets (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Current Assets for 11 consecutive years, with $6.2 billion as the latest value for Q4 2025.

  • Quarterly Current Assets rose 56.17% to $6.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.2 billion through Dec 2025, up 56.17% year-over-year, with the annual reading at $6.2 billion for FY2025, 56.17% up from the prior year.
  • Current Assets for Q4 2025 was $6.2 billion at BeOne Medicines, up from $5.7 billion in the prior quarter.
  • The five-year high for Current Assets was $7.6 billion in Q4 2021, with the low at $3.1 billion in Q4 2022.
  • Average Current Assets over 5 years is $4.9 billion, with a median of $4.4 billion recorded in 2021.
  • The sharpest move saw Current Assets tumbled 59.33% in 2022, then surged 56.17% in 2025.
  • Over 5 years, Current Assets stood at $7.6 billion in 2021, then crashed by 59.33% to $3.1 billion in 2022, then surged by 35.74% to $4.2 billion in 2023, then decreased by 5.04% to $4.0 billion in 2024, then soared by 56.17% to $6.2 billion in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $6.2 billion, $5.7 billion, and $4.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.